Tami Ellis

Responsible for Change Control Process and Agile PLM implementation site team.

Role: Project Document Manager at Tonix Pharmaceuticals
Location: Sharon, MA, US
LinkedIn followers: 500 followers

Manufacturing & ProductionView LinkedIn profile

About Tami Ellis

Experienced Document Control and Records Manager with a demonstrated history of working…

Experience

Project Document Manager
Tonix Pharmaceuticals
Feb 2022 — Present · US
Expert level documentation professional with experience in all phases of documentation control, processes, and record retention.

Education

Johnson & Wales University
BS
1987 — 1989

Skills

Medical Devices
Process Engineering
Microsoft Project
Auditing
Quality Assurance
Time Management
Management
Team Building
Microsoft Excel
Automation
Fda
Budgets
Cross-Functional Team Leadership
Quality System
Software Documentation
Engineering
Training
Project Management
Microsoft Office

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@tonixpharma.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Tonix Pharmaceuticals

Pharmaceutical Manufacturing · 182 employees · Founded 2007 · Berkeley Heights, New Jersey, United States

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases with high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com. *Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

tonixpharma.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Tami Ellis

Experience

Project Document Manager

Education

Johnson & Wales University

Skills

Find verified contacts for anyone on LinkedIn